Noninvasive prenatal test raises concern over screening strategies and the role of ultrasound;Nicht invasiver Chromosomentest wirft neue Fragen in der Pra7die;nataldiagnostik nach der Bedeutung des Ultraschalls und Fragen nach neuen Screeningstrategien auf

Ultraschall in der Medizin

Volumn 34, Issue 5, 2013, Pages 417-420

  Tercanli, S ^a   Vial, Y ^b   Merz, E ^b  

^a Ultraschall Freie Strasse   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AMNIOCENTESIS; ANEUPLOIDY; BLOOD; CELL FREE SYSTEM; CHORION VILLUS SAMPLING; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; DOWN SYNDROME; EDITORIAL; FEMALE; FETOMATERNAL TRANSFUSION; FETUS ECHOGRAPHY; GENETIC SCREENING; GENETICS; HUMAN; KARYOTYPING; METHODOLOGY; NEWBORN; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE; PREGNANCY; PRENATAL DIAGNOSIS; TRISOMY;

ADULT; AMNIOCENTESIS; ANEUPLOIDY; CELL-FREE SYSTEM; CHORIONIC VILLI SAMPLING; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DNA; DOWN SYNDROME; FEMALE; GENETIC TESTING; HUMANS; INFANT, NEWBORN; KARYOTYPING; MATERNAL-FETAL EXCHANGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PRENATAL DIAGNOSIS; TRISOMY; ULTRASONOGRAPHY, PRENATAL;

EID: 84886937679     PISSN: 01724614     EISSN: 14388782     Source Type: Journal    
DOI: 10.1055/s-0033-1350597     Document Type: Editorial

References (12)

1. Morain S., Greene M. F., Mello M. M. A new era in noninvasive prenatal testing. N Engl J Med: 2013; 369 06 499 501 10.1056/NEJMp1304843 Epub 2013 Jul 17
2. Nicolaides K. H. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn: 2011; 31 7 15
3. Merz E., Thode C., Alkier A. et al. A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall in Med: 2008; 29 639 645
4. Malone F. D., Canick J. A., Ball R. H. et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med: 2005; 353 2001 2011 (Pubitemid 41609093)
5. Lüthgens K., Abele H., Alkier R. et al. Cross-validation of the first trimester screening algorithm of the FMF London on 38,700 pregnancies in Germany. Ultraschall in Med: 2011; 32 367 372
6. Ekelund C. K., Jorgensen F. S., Petersen O. B. et al. Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study. BMJ: 2008; 337 a2547 10.1136/bmj.a2547
7. Bianchi D. W., Simpson J. L., Jackson L. G. et al. Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. National Institute of Child Health and Development Fetal Cell Isolation Study. Prenat Diagn: 2002; 22 609 615 (Pubitemid 34839302)
8. Walsh J. ME, Goldberg J. D. Fetal aneuploidy detection by maternal plasma DNA sequencing: a technology assessment. Prenat Diagn: 2013; 33 514 520
9. Agarwal A., Sayres L. C., Cho M. K. et al. Commercial landscape of noninvasive prenatal testing in the United States. Prenat Diagn: 2013; 33 521 531
10. Gregg A. R., Gross S. J., Best R. G. et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med: 2013; 15 395 398
11. Benn P., Borell A., Chiu R. et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn: 2013; 33 07 622 629 Epub 2013 May 21 10.1002/pd.4139
12. Reiss R. E., Cherry A. M. Still a screening test: more attention needed to noninvasive prenatal test false-positive rates. Am J Obstet Gynecol: 2013